FDx Advisors Inc. lifted its position in shares of CVS Health Corp (NYSE:CVS) by 77.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 63,320 shares of the pharmacy operator’s stock after acquiring an additional 27,736 shares during the period. FDx Advisors Inc.’s holdings in CVS Health were worth $4,149,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in the company. Bell Rock Capital LLC grew its position in CVS Health by 764.0% in the 4th quarter. Bell Rock Capital LLC now owns 432 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 382 shares in the last quarter. Daiwa SB Investments Ltd. bought a new position in CVS Health in the 4th quarter valued at about $30,000. Acima Private Wealth LLC bought a new position in CVS Health in the 4th quarter valued at about $33,000. Cornerstone Advisors Inc. grew its position in CVS Health by 71.6% in the 3rd quarter. Cornerstone Advisors Inc. now owns 508 shares of the pharmacy operator’s stock valued at $40,000 after buying an additional 212 shares in the last quarter. Finally, Certified Advisory Corp grew its position in CVS Health by 46.3% in the 4th quarter. Certified Advisory Corp now owns 638 shares of the pharmacy operator’s stock valued at $42,000 after buying an additional 202 shares in the last quarter. Institutional investors and hedge funds own 84.55% of the company’s stock.
Shares of NYSE CVS opened at $55.60 on Friday. CVS Health Corp has a twelve month low of $51.93 and a twelve month high of $82.15. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.03 and a quick ratio of 0.65. The stock has a market capitalization of $70.89 billion, a price-to-earnings ratio of 7.85, a price-to-earnings-growth ratio of 1.06 and a beta of 0.95.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 3rd. Shareholders of record on Tuesday, April 23rd will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date is Monday, April 22nd. CVS Health’s dividend payout ratio is presently 28.25%.
In other CVS Health news, insider Larry J. Merlo sold 166,368 shares of the company’s stock in a transaction dated Tuesday, January 8th. The shares were sold at an average price of $69.04, for a total transaction of $11,486,046.72. Following the completion of the sale, the insider now directly owns 496,577 shares of the company’s stock, valued at $34,283,676.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jonathan C. Roberts sold 77,639 shares of the company’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $64.54, for a total transaction of $5,010,821.06. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 23,600 shares of company stock valued at $1,270,896 and have sold 412,039 shares valued at $27,326,012. 0.53% of the stock is currently owned by corporate insiders.
CVS has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on shares of CVS Health in a research report on Sunday, December 2nd. They issued an “overweight” rating and a $77.84 target price for the company. UBS Group assumed coverage on shares of CVS Health in a research report on Thursday, January 17th. They issued a “buy” rating and a $75.00 target price for the company. Bank of America reissued a “buy” rating and issued a $92.00 price target on shares of CVS Health in a report on Thursday, January 3rd. ValuEngine downgraded shares of CVS Health from a “sell” rating to a “strong sell” rating in a report on Thursday, February 28th. Finally, SunTrust Banks cut their price target on shares of CVS Health to $85.00 and set a “buy” rating for the company in a report on Thursday, February 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $84.18.
TRADEMARK VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2019/03/17/fdx-advisors-inc-purchases-27736-shares-of-cvs-health-corp-cvs.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
See Also: Fundamental Analysis
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.